Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer
Language: 
English
Abstract: 

Paclitaxel is an active agent for adenocarcinomas and squamous cell carcinomas of the esophagus and is a radiation sensitizer. We sought to investigate the toxicity and complete response rate of paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Forty-one patients with esophageal cancer were studied, 29 with adenocarcinomas and 12 with squamous cell cancers. Twelve patients had tumor extension into the proximal stomach and/or abdominal adenopathy. Patients received paclitaxel 60 mg/m2 by 3-hour intravenous (i.v.) infusion, and cisplatin 25 mg/m2 weekly on days 1, 8, 15, and 22. Radiation was administered concurrently to a total dose of 39.60 Gy, in 1.80 Gy fractions, for 22 treatments. Patients with medical or surgical contraindications to esophagectomy received 2 additional weeks of paclitaxel with a radiation boost to 50.4 Gy. Neutropenia was the most common grade 3/4 toxicity occurring in 10 patients (24%). Only 2 patients (5%) had grade 4 esophagitis requiring parenteral nutrition. Twelve patients (29%) obtained a complete response. The 2-year progression-free and overall survival rates were 40% and 42%, respectively. Esophagitis was less severe than expected and prophylactic enteral feeding tubes were not necessary. Additional effective systemic treatments are needed to reduce the development of distant metastases.

Author(s): 
Safran, H.
Gaissert, H.
Akerman, P.
Hesketh, P. J.
Chen, M. H.
Moore, T.
Koness, J.
Graziano, S.
Wanebo, H. J.
Item Type: 
Journal Article
Publication Title: 
Cancer Investigation
Journal Abbreviation: 
Cancer Invest.
Publication Date: 
2001
Publication Year: 
2001
Pages: 
7-Jan
Volume: 
19
Issue: 
1
ISSN: 
0735-7907
Library Catalog: 
NCBI Published Medical (?)
Extra: 
PMID: 11291548

Turabian/Chicago Citation

H. Safran, H. Gaissert, P. Akerman, P. J. Hesketh, M. H. Chen, T. Moore, J. Koness, S. Graziano and H. J. Wanebo. 2001. "Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer." Cancer Investigation 19: 1: 7-Jan.

Wikipedia Citation

<ref> {{Cite journal | doi = | issn = 0735-7907 | volume = 19 | pages = 7-Jan | last = Safran | first = H. | coauthors = Gaissert, H., Akerman, P., Hesketh, P. J., Chen, M. H., Moore, T., Koness, J., Graziano, S., Wanebo, H. J. | title = Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer | journal = Cancer Investigation | date = 2001 | pmid = | pmc = }} </ref>